Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, Boston Scientific (BSX) stood at $102.67, denoting a +1.97% change from the preceding trading day.
Fed's Stagflation Fears Weigh, Yet Growth Factors Make BSX Stock a Buy
Boston Scientific, with substantial operations in China and Europe, faces significant risks due to escalating global trade tensions in 2025.
Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?
Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and WATCHMAN's performance.
Boston Scientific Gains 42.2% in a Year: What's Driving the Stock?
BSX's shares rise on the back of its innovative product portfolio and impressive value-added acquisition. However, the unfavorable macroeconomic scenario is concerning.
Is Trending Stock Boston Scientific Corporation (BSX) a Buy Now?
Boston Scientific (BSX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Boston Scientific Corporation (BSX) TD Cowen 45th Annual Healthcare Conference (Transcript)
Boston Scientific Corporation (NYSE:BSX ) TD Cowen 45th Annual Healthcare Conference March 4, 2025 9:10 AM ET Company Participants Dan Brennan - Chief Financial Officer Ken Stein - Chief Medical Officer Art Butcher - Executive Vice President, MedSurg and APAC Conference Call Participants Josh Jennings - TD Cowen Josh Jennings Good morning. I'm Josh Jennings from the TD Cowen Medical Devices research team, and joined by Brian Kennedy and Eric Anderson, and we're excited to kick off Day 2 of the 45th Annual TD Cowen Healthcare Conference and thrilled to have executives from the Boston Scientific management team joining us and spending time with us this week.
BSX Stock Set to Gain From the New Agreement to Acquire SoniVie Ltd.
Boston Scientific inks a deal to acquire the remaining 90% stake in SoniVie Ltd.
Why Boston Scientific (BSX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
Here is how Boston Scientific (BSX) and Abivax SA Sponsored ADR (ABVX) have performed compared to their sector so far this year.
Boston Scientific Expects Strong Gains in 2025: Time to Buy the Stock?
Boston Scientific begins 2025 on a solid note, expecting organic revenue growth of 14% to 16% in the first quarter.
EMEA Expansion to Support BSX Stock Amid Fierce Competition
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
